Archiwa #ObesityTreatment

Retatrutide Weight Loss Breakthrough: Triple-Hormone Drug Matches Surgery Results

May 24, 2026 by Airpres Admin

retatrutide weight loss triple agonist obesity drug editorial cover

Eli Lilly’s retatrutide weight loss trial achieved up to 30.3% body weight reduction, matching bariatric surgery. Phase 3 TRIUMPH-1 data, mechanism, and access analysis.

FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill Foundayo, Igniting a New Battle in the Obesity Market

April 5, 2026 by admin

GLP-1 weight loss pill bottle Foundayo on a kitchen table

FDA approves Eli Lilly’s GLP-1 weight loss pill Foundayo. A once-daily oral drug that could transform obesity care. Read analysis.

The End of the Injection Era? FDA Fast-Tracks Eli Lilly’s ‘Foundayo’ Obesity Pill in Historic 50-Day Review

April 2, 2026 by admin

Foundayo weight-loss pill macro photography with molecular structure inside on dark reflective surface

The FDA just approved Eli Lilly’s Foundayo weight-loss pill. Discover how this restriction-free, $149 daily oral GLP-1 will change global obesity care.

Retatrutide Weight Loss Breakthrough: Triple-Hormone Drug Matches Surgery Results

FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill Foundayo, Igniting a New Battle in the Obesity Market

The End of the Injection Era? FDA Fast-Tracks Eli Lilly’s ‘Foundayo’ Obesity Pill in Historic 50-Day Review

The Kielce Pogrom of 1946: How Soviet NKVD Agents Orchestrated the Massacre and Blamed the Polish Underground

Yunzhi (Trametes versicolor) in Cancer Support: The Registered Chinese Drug, Evidence, and Safe Use

A Polish Boy Dies in England: Who Has Greater Rights — And Are the British Already Under Occupation?

SEC Approves Nasdaq Bitcoin Index Options — But a $1.55 Billion ETF Exodus Tells a Different Story

The Trial of the Sixteen: Stalin’s Judicial Murder of Poland’s Underground State — And How the West Stayed Silent

AI Capability Jump 2026: Morgan Stanley Warns Breakthrough Will Reshape Global Economy